Skip to main content
Company profile
Arvinas, Inc. logo

Arvinas, Inc.

Pipeline7 assets

  • ARV-102ARV-102 / LRRK2 / oral brain-penetrant PROTAC degrader / Neurology
    Parkinson’s diseasePhase 1/1bunder investigationProgressive supranuclear palsyunder investigation
  • ARV-027ARV-027 / polyQ-AR / oral peripherally restricted PROTAC degrader / Neurology
    Spinal-bulbar muscular atrophyPhase 1/1bunder investigation
  • ARV-806ARV-806 / KRAS G12D / PROTAC degrader / Oncology
    Pancreatic cancerPhase 1/1bunder investigationColorectal cancerPhase 1/1bunder investigationNon-small cell lung cancerPhase 1/1bunder investigation
  • ARV-393ARV-393 / BCL6 / oral PROTAC degrader / Oncology
    Non-Hodgkin lymphoma / B-cell malignanciesPhase 1/1bunder investigation
  • ARV-6723ARV-6723 / HPK1 / oral PROTAC degrader / Oncology
    Advanced solid tumorsPreclinicalunder investigation
  • VepdegestrantARV-471 / ER / oral PROTAC estrogen receptor degrader / Oncology
    ER+/HER2- locally advanced or metastatic breast cancerPhase 3under investigation
  • LuxdegalutamideARV-766; JSB462 / AR / oral PROTAC androgen receptor degrader / Oncology
    Prostate cancerPhase 2under investigation

Latest news15 items

All news

Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease

– Data showed improvements in an objective measure of impaired eye movement associated with Parkinson’s disease, with a correlation between reductions in LRRK2 cerebrospinal fluid (CSF) biomarkers to these changes in oculomotor function and changes in synaptic biomarkers – – Findings support

Presentation / Abstract • Phase 1MDS 2026 late-breaking oral presentation Wed, Oct 7, 2026, 12:30 PM ET

Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders®

NEW HAVEN, Conn., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that novel biomarker data from a Phase 1 clinical trial of ARV-102 in participants with

Presentation / Abstract • Phase 1Late-breaking oral presentation Wed, Oct 7, 2026, 12:30 PM ET

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted an option to purchase 64,766 shares of

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that that management will participate in fireside chats at the

Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) (“Arvinas” or the “Company”), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the Company granted 45,696 restricted stock units (“RSU”) to

Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026

NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review second quarter 2026 financial results and provide a corporate update during a

Arvinas to Present at Jefferies Global Healthcare Conference

NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare

Arvinas Employees Give Back During Company-wide Impact Day

NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that employees across Connecticut, in the Greater Boston area, and around the

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

– First-ever FDA approved PROTAC supports the further development and potential of Arvinas’ pipeline – – Announced FDA Approval of VEPPANU ™ (vepdegestrant) for the treatment of ESR1m, ER+/HER2- advanced breast cancer – – Announced selection of Rigel Pharmaceuticals for the exclusive global rights

Presentation / Abstract • Phase 1

Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026

NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2026 financial results and provide a corporate update

Arvinas, Inc. • Endpoint Arena